Guidelines for high dose chemotherapy and stem cell transplantation for
systemic AL amyloidosis: EHA-ISA working group guidelines
- Publication date
- Publisher
Abstract
AL amyloidosis is a systemic amyloidosis and is associated with an
underlying plasma cell dyscrasia. High dose intravenous melphalan and
autologous stem cell transplantation was developed for the treatment of
AL amyloidosis in the early 1990s and was prompted by its success in
multiple myeloma. This application has evolved significantly over the
past three decades. These guidelines provide a comprehensive assessment
of eligibility criteria, stem cell collection and mobilisation
strategies and regimens, risk-adapted melphalan dosing, role for
induction and consolidation therapies, specific supportive care
management, long-term outcome with respect to survival, haematologic
response and relapse and organ responses following stem cell
transplantation. These guidelines are developed by the experts in the
field on behalf of the stem cell transplant working group of the
International Society of Amyloidosis (ISA) and European Haematology
Association (EHA)